Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is a novel target of lung cancer stem-like cell immunotherapy.
Horibe R, Hirohashi Y, Asano T, Mariya T, Suzuki T, Takaya A, Saijo H, Shionoya Y, Kubo T, Nakatsugawa M, Kanaseki T, Tsukahara T, Watanabe K, Atsuyama E, Toji S, Hirano H, Hasegawa T, Takahashi H, Sato N, Torigoe T.
Horibe R, et al. Among authors: hasegawa t.
PLoS One. 2017 Mar 1;12(3):e0171460. doi: 10.1371/journal.pone.0171460. eCollection 2017.
PLoS One. 2017.
PMID: 28248963
Free PMC article.